论文部分内容阅读
目的探讨依达拉奉联合灯盏花素对脑梗死急性期的治疗作用。方法将120例经头颅计算机断层扫描(CT)或磁共振扫描(MRI)确诊为脑梗死的患者,依据随机化分组,开展随机对照研究。在西医神经内科常规治疗和规范护理康复的基础上,分为治疗组(西医常规加依达拉奉和灯盏花素治疗组)60例,对照组(西医常规治疗组)60例。对患者的神经功能和日常生活能力进行动态观察,评价疗效。结果治疗组总有效率为83.3%,对照组为65.0%,治疗组明显优于对照组(P<0.01);治疗组的血液流变学、血脂等指标的改变也优于对照组。研究中未发现与使用药物等治疗有关的不良反应。结论依达拉奉加用灯盏花素能明显地改善脑梗死急性期患者的神经功能。
Objective To investigate the therapeutic effect of edaravone combined with breviscapine on acute cerebral infarction. Methods A total of 120 patients with cerebral infarction who were diagnosed by CT or MRI were randomly divided into randomized controlled trials. On the basis of conventional treatment of Western medicine and standard nursing care, 60 cases were divided into treatment group (Western routine plus edaravone and breviscapine treatment group), and control group (Western conventional treatment group) 60 cases. The patient’s neurological function and daily living ability of dynamic observation, evaluation of efficacy. Results The total effective rate was 83.3% in the treatment group and 65.0% in the control group, which was significantly better in the treatment group than in the control group (P <0.01). The changes of hemorheology and blood lipid in the treatment group were also better than those in the control group. No side effects associated with treatment with drugs were found in the study. Conclusion Edaravone plus Breviscapine can significantly improve the neurological function in patients with acute cerebral infarction.